The Cognite Atlas AI™ Definitive Guide to Industrial Agents Launched as the Premiere AI Manual for Industry
5.9.2024 15:00:00 CEST | Business Wire | Press release
The book is a must-read for transformation leaders looking to accelerate AI innovation and reduce time to value of their digital transformation programs
Cognite, the globally recognized authority in AI for industry, today announcedthe launch ofThe Cognite Atlas AI™Definitive Guide to Industrial Agents, a comprehensive manual for companies looking to accelerate the development and scale of AI solutions and reduce time to value.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904796303/en/
The Cognite Atlas AI™ Definitive Guide to Industrial Agents Launched as the Premiere AI Manual for Industry. (Photo: Business Wire)
The book explores advancements in AI over the past year and expands on industrial AI agents and the latest technological requirements necessary to make AI work for industry. The Cognite Atlas AI™ Definitive Guide to Industrial Agents offers real-world examples, practical advice, and tools digital leaders can use to implement AI agents that can improve decision-making processes and help their organizations achieve higher productivity, safety, and overall operational efficiency.
“According to a recent ARC Advisory Group Digital Transformation, Sustainability, and Technology survey, AI is the most impactful technology we'll see over the next five years,” said Janice Abel, ARC Advisory Group Principal Technology Analyst. “The Cognite Atlas AI™ Definitive Guide to Industrial Agents is a practical place to start for digital leaders looking to make AI work in complex industrial environments.”
“Cognite Atlas AI enables us to use AI to enhance decision-making and improve efficiency, like with an industrial agent fine-tuned to understand unstructured technical documentation and Aker BP’s equipment hierarchy," said Paula Doyle, Chief Digital Officer at Aker BP. "By implementing the Document Parser AI Agent, we are streamlining our equipment management process, saving thousands of hours of data-punching, and refocusing our experts on business problems that really matter to the short- and long-term success of our operation.”
“Data lakes and copilots are just the beginning. Industrial AI demands more than a one-size-fits-all approach,” said Paul Grenet, Chief Revenue Officer at Cognite. “Cognite Atlas AI unlocks the full potential of generative AI for industry with industrial agents that can accelerate efficiencies and generate tens of millions of dollars in business impact. These agents enable a new wave of intelligent, domain-specific applications that revolutionize how industries operate."
The Cognite Atlas AI™ Definitive Guide to Industrial Agents is the third installment of the Cognite Definitive Guide series, which also includes The Definitive Guide to Generative AI for Industryand The Definitive Guide to Industrial DataOps. The series demystifies industrial digitalization and helps make sense of the journey industrial companies must take to evaluate, adopt, and scale AI solutions across their organizations.
The full digital version of the book is available online for free. Physical copies are available by request. Visit Cognite.ai to learn more.
About Cognite
Cognite makes Generative AI work for industry. Leading energy, manufacturing, and power & renewables enterprises choose Cognite to deliver secure, trustworthy, and real-time data to transform their asset-heavy operations to be safer, more sustainable, and more profitable. Cognite provides a user-friendly, secure, and scalable platform that makes it easy for all decision-makers, from the field to remote operations centers, to access and understand complex industrial data, collaborate in real-time, and build a better tomorrow. Visit us at www.cognite.ai and follow us on LinkedIn and Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904796303/en/
Contacts
Michelle Holford
Michelle Holford
Vice President, Global PR, Cognite
Michelle.holford@cognite.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom